Alzheimer’s Disease – Landscape & Forecast – Disease Landscape & Forecast (G7)
Eisai / Biogen’s lecanemab (Leqembi) and Eli Lilly’s Kisunla (donanemab) have launched for the treatment of early Alzheimer’s disease (AD) in the United States and Japan and, after early headwinds, are nearing market in Europe. Early uptake of the anti-Aβ MAbs has been slow, but market-building efforts to drive awareness and streamline diagnosis are ongoing. New formulations (e.g., subcutaneous lecanemab) and potentially disruptive DMTs (e.g., Roche’s trontinemab, Eli Lilly’s remternetug, Novo Nordisk’s semaglutide) are advancing in the pipeline. Lundbeck / Otsuka’s brexpiprazole (Rexulti) is FDA-approved to treat agitation in AD, and other novel therapies, including Axsome’s dextromethorphan-bupropion (Auvelity) and Karuna’s xanomeline-trospium (Cobenfy), are progressing through late-phase development to treat the neuropsychiatric symptoms of AD. The launch of these potential blockbusters could meaningfully alter this market’s dynamics, driven by unmet clinical need, market demand, and brand-level pricing.
- How will competition between current and emerging anti-Aβ MAbs evolve through 2034?
- How do KOLs perceive recently approved and emerging neuropsychiatric therapies for AD? What are the key opportunities for differentiation in this area?
- What are the key drivers of and constraints on the AD market, and how might they change over the forecast period?
- What impact could the launch of an oral DMT have on the market?
Product description
Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:
- Optimize your long-term disease and development strategy.
- Quantify market potential for your pipeline assets and those of your competitors.
- Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
- Gauge the commercial outlook and impact of key market events.
Table of contents
- Alzheimer's Disease - Landscape & Forecast - Disease Landscape & Forecast (G7)
- Executive Summary
- Key Updates
- Market Forecast
- Disease Context
- Epidemiology
- Key takeaways
- Total asymptomatic Alzheimeru2019s disease prevalent cases
- Total MCI due to AD prevalent cases
- Total Alzheimer's disease prevalent cases
- Total Alzheimer's disease prevalent cases by severity
- Diagnosed Alzheimer's disease prevalent cases by symptom status
- Diagnosed and drug-treated populations
- Key takeaways
- Current Treatment
- Key takeaways
- Treatment for Alzheimer's disease
- Treatment decision tree for Alzheimer's disease: United States
- Treatment decision tree for behavioral symptoms of Alzheimer's disease: United States
- Treatment decision tree for Alzheimer's disease: Europe
- Treatment decision tree for behavioral symptoms of Alzheimer's disease: Europe
- Treatment decision tree for Alzheimer's disease: Japan
- Treatment decision tree for behavioral symptoms of Alzheimer's disease: Japan
- Key current therapies
- Key takeaways
- Emerging Therapies
- Drug Pipeline
- Appendix
- Executive Summary
